How many years of cash runway do biotechs need to feel comfortable? Two? Three? Eliem Therapeutics has decided its two years of cash looks dicey in the current capital environment—and has responded by shelving a phase 2-ready depression drug candidate and laying off 55% of staff in a pivot to preclinical.
AbbVie is setting the stage for an aggressive M&A push to fill the revenue vacuum left by Humira, with CEO Richard Gonzalez telling investors to expect a move if the shoe fits.
Scroll through AstraZeneca’s pipeline of new drug candidates in development and there remains one glaring omission. The Big Pharma that brought one of the world’s most widely used COVID-19 shots to market doesn’t have any more vaccines in development and only has a single new immune therapy in the clinic.
Just a few weeks after being newly reborn as a standalone public company, GE HealthCare is going through a growth spurt.
Failed clinical trials have put Vistagen on edge. After seeing two rival social anxiety disorder candidates flunk phase 2 studies, the biotech has paused plans to resume a phase 3 trial of its own once-failed prospect PH94B pending talks with the FDA.
Eli Lilly’s Renee Williams arrived in New York City this week ready to mix and mingle with dozens of biotechs that had descended on the Big Apple itching to strike a deal.
Lantheus, maker of a broad range of diagnostics, therapeutics and artificial intelligence-powered platforms, is adding another radiopharmaceutical to its collection.
The FDA has cleared an artificial intelligence program designed to provide a helping hand to clinicians conducting cardiac ultrasound exams developed by DiA Imaging Analysis.
Johnson & Johnson has yet to publicly detail the R&D overhaul reported last week by Fierce Pharma, and, apparently, at least one company with work that may be deprioritized or reorganized is waiting in the lurch.
Clinicians and researchers have suspected for years that an aggressive, less-common form of multiple sclerosis (MS) is likely a distinct form of the disease. Now, new research conducted using a more accurate mouse model confirms it.